Alto Neuroscience, Inc. (ANRO): R&D Expense
$45.62M
Year ended 2025-12-31
$64.92M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $45.62M | -2.9% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $47.00M | +55.1% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $30.29M | n/a | 2025-03-20, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $45.62M | -2.9% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $61.12M | -27.7% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $11.90M | -79.0% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $23.39M | +27.6% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $99.13M | -0.2% |
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $33.48M | -15.0% |
| PepGen Inc. (PEPG) | 2025-12-31 | $71.04M | -7.1% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $174.09M | +25.7% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $85.47M | -9.6% |
Compare ANRO, LXRX, FBIO, BNTC side by side · Screen every company in Pharmaceutical Preparations ↗